<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Wood, D.</title>
    <link>http://repub.eur.nl/res/aut/7166/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>The Cardiology Information System: the need for data standards for integration of systems for patient care, registries and guidelines for clinical practice (Article)</title>
      <link>http://repub.eur.nl/res/pub/9937/</link>
      <pubDate>2002-08-01T00:00:00Z</pubDate>
      <description>The building blocks come together, finally! Already three decades ago we were dreaming of the complete Cardiology Information System. However, at that time the computer programmers explained that it was too early. In the subsequent year information tech- nology (IT) specialists, replacing the programmers, gave similar messages. Business interests of medical equipment industries seemed not to support data exchange; however this has changed in recent years. Now, finally the pieces come together. The bricks have been laid, the blocks have been made, and the system can be built.</description>
    </item> <item>
      <title>Registration and management of smoking behaviour in patients with coronary heart disease. The EUROASPIRE survey. (Article)</title>
      <link>http://repub.eur.nl/res/pub/12816/</link>
      <pubDate>1999-11-01T00:00:00Z</pubDate>
      <description>AIMS: To establish to what extent smoking status and its management is
          recorded in coronary patients' medical records, and to investigate their
          motivation to change smoking behaviour. METHODS: In EUROASPIRE, a survey
          on secondary prevention in 21 hospitals in the Czech Republic, Finland,
          France, Germany, Hungary, Italy, the Netherlands, Slovenia and Spain, data
          were collected from records of 4863 consecutive patients =&lt;70 years of
          age, with previous (&gt;6 months) admission for coronary bypass operation,
          angioplasty, myocardial infarction or ischaemia. Of these, 3569 patients
          were interviewed 1.6 years following their index hospitalization. RESULTS:
          Of the 82% of patients whose pre-hospitalization smoking behaviour was
          known, 34% were smokers. Documentation was significantly better in younger
          patients, in males and patients requiring angioplasty or bypass operation.
          In only 35% of 1364 smokers was the smoking habit recorded again after
          discharge from hospital At the time of the interview, 554 of the
          interviewed patients were still smoking. In over 90% of the smokers,
          advice to quit smoking was reported at interview. A positive relationship
          was found between receiving advice and seeking help to stop smoking,
          between receiving advice to stop smoking and attempting to stop, as well
          as between seeking help and attempting to stop. CONCLUSION: In almost 20%
          of coronary patients, smoking habits are not documented in medical
          records, and in only 35% of the smoking patients is smoking status
          documented at the follow-up. After a cardiac event requiring
          hospitalization as many as 50% of patients continue their smoking habit
          and so there is further potential to reduce the risk of recurrent coronary
          disease. Advice to stop smoking motivates patients to seek help and to
          attempt to stop smoking. Physicians repeated advice to stop smoking is
          important and smoking status should always be documented at follow-up.</description>
    </item> <item>
      <title>Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty (Article)</title>
      <link>http://repub.eur.nl/res/pub/4288/</link>
      <pubDate>1988-01-30T00:00:00Z</pubDate>
      <description>A randomised trial of 367 patients with acute myocardial infarction was performed to determine whether an invasive strategy combining thrombolysis with recombinant tissue-type plasminogen activator (rTPA), heparin, and acetylsalicylic acid, and immediate percutaneous transluminal coronary angioplasty (PTCA) would be superior to a noninvasive strategy with the same medical treatment but without immediate angiography and PTCA. Intravenous infusion of 100 mg rTPA was started within 5 h after onset of symptoms (median 156 min). Angiography was performed 6-165 min later in 180 out of 183 patients allocated to the invasive strategy; 184 patients were allocated to the non-invasive strategy. Immediate PTCA reduced the percentage stenosis of the infarct-related segment, but this was offset by a high rate of transient (16%) and sustained (7%) reocclusion during the procedure and recurrent ischaemia during the first 24 h (17%). The clinical course was more favourable after non-invasive therapy, with a lower incidence of recurrent ischaemia within 24 h (3%), bleeding complications, hypotension, and ventricular fibrillation. Mortality at 14 days was lower in patients allocated to non-invasive treatment (3%) than in the group allocated to invasive treatment (7%). No difference between the treatment groups was observed in infarct size estimated from myocardial release of alpha-hydroxybutyrate dehydrogenase or in left ventricular ejection fraction after 10-22 days. Since immediate PTCA does not provide additional benefit there seems to be no need for immediate angiography and PTCA in patients with acute myocardial infarction treated with rTPA.</description>
    </item> <item>
      <title>Thrombolysis with rt-PA in acute myocardial infarction: no additional benefit of immediate PTCA (Miscellaneous)</title>
      <link>http://repub.eur.nl/res/pub/5368/</link>
      <pubDate>1988-01-30T00:00:00Z</pubDate>
      <description>A randomised trial of 367 patients with acute myocardial infarction was performed to determine whether an invasive strategy combining thrombolysis with recombinant tissue-type plasminogen activator (rTPA), heparin, and acetylsalicylic acid, and immediate percutaneous transluminal coronary angioplasty (PTCA) would be superior to a noninvasive strategy with the same medical treatment but without immediate angiography and PTCA. Intravenous infusion of 100 mg rTPA was started within 5 h after onset of symptoms (median 156 min). Angiography was performed 6-165 min later in 180 out of 183 patients allocated to the invasive strategy; 184 patients were allocated to the non-invasive strategy. Immediate PTCA reduced the percentage stenosis of the infarct-related segment, but this was offset by a high rate of transient (16%) and sustained (7%) reocclusion during the procedure and recurrent ischaemia during the first 24 h (17%). The clinical course was more favourable after non-invasive therapy, with a lower incidence of recurrent ischaemia within 24 h (3%), bleeding complications, hypotension, and ventricular fibrillation. Mortality at 14 days was lower in patients allocated to non-invasive treatment (3%) than in the group allocated to invasive treatment (7%). No difference between the treatment groups was observed in infarct size estimated from myocardial release of alpha-hydroxybutyrate dehydrogenase or in left ventricular ejection fraction after 10-22 days. Since immediate PTCA does not provide additional benefit there seems to be no need for immediate angiography and PTCA in patients with acute myocardial infarction treated with rTPA.</description>
    </item> <item>
      <title>Thrombolytic therapy and percutaneous coronary angioplasty (Article)</title>
      <link>http://repub.eur.nl/res/pub/5378/</link>
      <pubDate>1988-01-01T00:00:00Z</pubDate>
      <description></description>
    </item>
  </channel>
</rss>